Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex
pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains …

Skin barrier dysfunction, a defining feature of atopic dermatitis (AD), arises from multiple
interacting systems. In AD, skin inflammation is caused by host–environment interactions …

Atopic dermatitis (AD) is a common inflammatory skin condition that has traditionally been
considered a paradigmatic type 2 immunity (T2)‐driven disease. Interleukin (IL)‐4 and IL‐13 …

Background Dupilumab is an IL-4 receptor α mAb inhibiting signaling of IL-4 and IL-13, key
drivers of type 2–driven inflammation, as demonstrated by its efficacy in patients with …

Atopic dermatitis (AD) is a chronic inflammatory skin condition that affects diverse ethnic
groups with varying prevalence. Despite a predominance of studies in individuals of …

Introduction: Atopic dermatitis (AD) is the most common inflammatory skin disease. It has a
complex pathophysiology, with a combination of immune dysregulation and intrinsic barrier …

Whole metagenome analysis has the potential to reveal functional triggers of skin diseases,
but issues of cost, robustness and sampling efficacy have limited its application. Here, we …

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. It often
precedes the development of food allergy and asthma. Recent insights into AD reveal …

Filaggrin Mutations Associated with Skin and Allergic Diseases | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Background Severe atopic dermatitis (AD) has a high unmet need for effective and safe
therapeutics. In early-phase trials, dupilumab, a fully human mAb targeting IL-4 receptor α …